The Lundquist Institute researchers discovered a natural compound that exhibits almost ideal male contraceptive effects in pre-clinical studies
LOS ANGELES — In a new paper published by Nature Communications, The Lundquist Institute (TLI) Investigator Wei Yan, MD, PhD, and his research colleagues spell out an innovative strategy that has led to the discovery of a natural compound as a safe, effective and reversible male contraceptive agent in pre-clinical animal models. Despite tremendous efforts over the past decades, the progress in developing non-hormonal male contraceptives has been very limited.
The grant will fund clinical trials to study the efficacy of psilocybin in treating the emotional suffering associated with terminal medical illness
LOS ANGELES — The Lundquist Institute has received a $1.75 million grant from the Steven & Alexandra Cohen Foundation to fund a multi-site clinical trial to evaluate the efficacy and safety of the compound psilocybin in individuals with severe psychological distress associated with a terminal medical illness. The grant will also support education and outreach programs related to the use of psilocybin within the field of palliative care.
Amgen Golden Ticket Winners to Receive Lab Space, Mentoring and Other Benefits
THOUSAND OAKS, Calif. – Amgen (NASDAQ:AMGN) today announced a three-year, Golden Ticket sponsorship of the BioLabs LA at The Lundquist Institute (TLI) life sciences co-working space to accelerate the development of new therapies, medical devices, and diagnostics to advance and improve human health. The BioLabs at TLI shared laboratory space was created to help high-potential life science and biotech startups overcome key obstacles for many early stage organizations, including: access to laboratory infrastructure, programming, and business development mentorship.
Ashraf S. Ibrahim, PhD, Lead Author, on publication in the world’s No. 1 Scientific Journal for Microbiology
LOS ANGELES — Today Nature Microbiology publishes The Lundquist Institute Investigator Dr. Ashraf Ibrahim and his co-authors’ paper, “Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis.”
In a Year Dominated by the Global COVID Pandemic, The Institute Kept Moving Forward
LOS ANGELES — The Lundquist Institute, a world leader in biomedical research, today released its 2020 Year in Review video. 2020 was an unparalleled year and given the challenge of working against the backdrop of the global COVID pandemic, the Institute had one of its most outstanding years ever.
California Institute for Regenerative Medicine (CIRM) Funds New Research on Nanotechnology for Stem Cell Implantation and Diabetes Treatment
LOS ANGELES — Two junior Investigators at the The Lundquist Institute, Dr. Eiji Yoshihara and Dr. Lina R. Nih, have received a Quest Award from the California Institute for Regenerative Medicine (CIRM). The Quest Award is for discovery research and aims to promote promising new technologies that could be translated for broad use and improved patient care.
First phase of plan includes up to 250,000 square feet of lab, manufacturing and office space
LOS ANGELES – The Lundquist Institute received unanimous approval from the Los Angeles County Board of Supervisors to begin development of a 15-acre biotech park, which will serve as a hub and catalyst for the region’s rapidly-developing bioscience industry.
Dr. Richard Casaburi is a world-renowned expert on COPD
LOS ANGELES – The Lundquist Institute investigator, Richard Casaburi, PhD, MD, has been presented with the European Respiratory Society’s (ERS) most prestigious honor, the Presidential Award, in recognition of his outstanding work to strengthen respiratory science and medicine worldwide. The award was presented during the ERS annual International Congress 2020 that welcomed more than 33,000 virtual attendees from around the world.
Second Live Virtual Webinar — COVID-19: Pregnancy, Infants & Children on Sept. 30 at 6pm PDT
LOS ANGELES — The Lundquist Institute has announced the second in its new series of online webinars, “The Lundquist Community Science Series.” This community service webinar series features internationally-renowned Lundquist investigators and clinician scientists, who will be addressing timely topics in areas of biomedical research and healthcare on a regular basis.
First participants received the shot at The Lundquist Institute on Friday, September 4; more injections scheduled next week
LOS ANGELES – The Lundquist Institute at Harbor-UCLA Medical Center officially began phase 3 trials of the Oxford University – AstraZeneca COVID-19 vaccine trial on Friday, September 4.